{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:19:11Z","timestamp":1793852351507,"version":"4.6.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.chest.2023.01.031","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T05:10:17Z","timestamp":1675919417000},"page":"1476-1491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Diagnosis and Management of Myositis-Associated Lung Disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Robert W.","family":"Hallowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-8977","authenticated-orcid":false,"given":"Sonye K.","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-009-1110-6","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"28","author":"Chen","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/kes167","article-title":"Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort","volume":"51","author":"Chua","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.002","article-title":"Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study","volume":"123","author":"Ji","year":"2010","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"Won Huh","year":"2007","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study","volume":"26","author":"Ye","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib7","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1007\/s00330-021-08411-w","article-title":"Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies","volume":"32","author":"Laporte","year":"2022","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2169\/internalmedicine.49.2889","article-title":"Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies","volume":"49","author":"Koreeda","year":"2010","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s100670200104","article-title":"Idiopathic inflammatory myopathy with diffuse alveolar damage","volume":"21","author":"Lee","year":"2002","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2003.006122","article-title":"Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis","volume":"63","author":"Fathi","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000488358","article-title":"Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respiration"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","article-title":"Classification, diagnosis, and management of idiopathic inflammatory myopathies","volume":"40","author":"Lazarou","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A\u00a0new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib23","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib25","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, etiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","article-title":"Clinical heterogeneity and outcomes of antisynthetase syndrome","volume":"15","author":"Hervier","year":"2013","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A\u00a0longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib158","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","article-title":"Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis","volume":"54","author":"Yamasak","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib32","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","article-title":"Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease","volume":"162","author":"Hirakata","year":"1999","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-J01- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"10.1016\/j.chest.2023.01.031_bib159","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2169\/internalmedicine.48.2207","article-title":"Nonspecific interstitial pneumonia (NSIP) associated with anti-KS antibody: differentiation from idiopathic NSIP","volume":"48","author":"Okayasu","year":"2009","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","article-title":"Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies","volume":"46","author":"Sato","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib161","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-J01 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib162","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"24","key":"10.1016\/j.chest.2023.01.031_bib163","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.2169\/internalmedicine.51.7452","article-title":"The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis\/dermatomyositis","volume":"51","author":"Kunimasa","year":"2012","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib164","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/art.24631","article-title":"Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease","volume":"60","author":"Richards","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib165","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/art.1780350718","article-title":"Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease","volume":"35","author":"Targoff","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib166","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jclinpath-2014-202367","article-title":"Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy","volume":"67","author":"Schneider","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib167","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib168","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"282","key":"10.1016\/j.chest.2023.01.031_bib31","first-page":"1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q\u00a0J Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s100670070030","article-title":"Clinical and serological aspects of patients with anti-Jo-1 antibodies\u2014an evolving spectrum of disease manifestations","volume":"19","author":"Schmidt","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-016-8528-9","article-title":"Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS Collaborative Group","volume":"52","author":"Cavagna","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib40","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"issue":"32","key":"10.1016\/j.chest.2023.01.031_bib41","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib42","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T\u00a0cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib43","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib44","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib49","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib50","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03009740802687455","volume":"38","author":"Fujikawa","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib52","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada","year":"2015","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib54","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","article-title":"Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib55","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"23","key":"10.1016\/j.chest.2023.01.031_bib56","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib57","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000552","article-title":"Muscle disease in scleroderma","volume":"30","author":"Paik","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib58","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3899\/jrheum.090652","article-title":"Interstitial lung disease associated with anti-PM\/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?","volume":"37","author":"Lega","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/art.22237","article-title":"Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy","volume":"55","author":"Selva-O'Callaghan","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/rheumatology\/35.4.305","article-title":"Polymyositis-associated overlap syndromes","volume":"35","author":"Venables","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.chest.2023.01.031_bib61","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/415272","article-title":"Anti-r052 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma","volume":"2012","author":"Ferreira","year":"2012","journal-title":"ISRN Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-R052 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"1012","key":"10.1016\/j.chest.2023.01.031_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/pgmj.2009.089656","article-title":"Diagnostic utility of anti-R052 detection in systemic autoimmunity","volume":"86","author":"Dugar","year":"2010","journal-title":"Postgrad Med J"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib65","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-R052 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-J01-positive patients with anti-R052 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140\u00a0kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib69","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib70","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib71","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib73","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib74","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/nar\/29.12.2517","article-title":"Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor","volume":"29","author":"Wang","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib75","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.chest.2023.01.031_bib76","author":"Liang"},{"key":"10.1016\/j.chest.2023.01.031_bib77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib78","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib169","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00408-019-00212-9","article-title":"Screening for myositis antibodies in idiopathic interstitial lung disease","volume":"197","author":"Fidler","year":"2019","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib79","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12890-021-01737-7","article-title":"Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies","volume":"21","author":"Misra","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib80","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.10-0194","article-title":"Connective tissue disease-associated interstitial lung disease: a call for clarification","volume":"138","author":"Fischer","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1164\/rccm.200702-220OC","article-title":"Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?","volume":"176","author":"Kinder","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib82","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1378\/chest.10-2662","article-title":"Autoimmune-featured interstitial lung disease: a distinct entity","volume":"140","author":"Vij","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib83","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.rmed.2012.09.005","article-title":"Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia\u2014with or without PM\/DM","volume":"107","author":"Takato","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2023.01.031_bib85","doi-asserted-by":"crossref","first-page":"2001205","DOI":"10.1183\/13993003.01205-2020","article-title":"Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype","author":"Graham","year":"2020","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib86","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.41415","article-title":"Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis","volume":"72","author":"Bernstein","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib87","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib88","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib89","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.rmed.2012.02.015","article-title":"Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6\u00a0min walk test","volume":"106","author":"Andersen","year":"2012","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib90","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCP.0000000000000599","article-title":"Pulmonary hypertension due to interstitial lung disease","volume":"25","author":"King","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib92","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","article-title":"Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases","volume":"49","author":"Hervier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib93","first-page":"260","article-title":"High-resolution computed tomography characterization of interstitial lung diseases in polymyositis\/dermatomyositis","volume":"35","author":"Hayashi","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib95","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ard.59.5.372","article-title":"Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy","volume":"59","author":"Kono","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib96","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.24372","article-title":"Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis","volume":"61","author":"Le Goff","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.chest.2023.01.031_bib97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fmed.2019.00239","article-title":"Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis\/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study","volume":"6","author":"Ning","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.chest.2023.01.031_bib98","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","article-title":"Polymyositis-dermatomyositis-associated interstitial lung disease","volume":"164","author":"Douglas","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2023.01.031_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106697","article-title":"Pulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies","volume":"191","author":"Flashner","year":"2022","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib100","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib101","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib102","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2169\/internalmedicine.37.669","article-title":"Clinical features of polymyositis\/dermatomyositis with steroid-resistant interstitial lung disease","volume":"37","author":"Takada","year":"1998","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib103","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A\u00a0retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib105","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib106","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.chest.2023.01.031_bib107","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib108","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10067-016-3443-2","article-title":"Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies","volume":"36","author":"Hayashi","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib110","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib111","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-J01-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib112","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08916930500124023","article-title":"Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants","volume":"38","author":"Takada","year":"2005","journal-title":"Autoimmunity"},{"issue":"9166","key":"10.1016\/j.chest.2023.01.031_bib115","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.chest.2023.01.031_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2015.12.004","article-title":"Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease","volume":"36","author":"Witt","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib117","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib118","first-page":"504","article-title":"Systematic review of the impact of drugs on diffuse interstitial disease associated with rheumatoid arthritis","volume":"17","author":"Cubero","year":"2020","journal-title":"Rheumatol Clin (Engl Ed)"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib119","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib120","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s10067-018-4314-9","article-title":"Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival","volume":"37","author":"England","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib121","first-page":"858","article-title":"Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome","volume":"37","author":"Casal-Dominguez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib122","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib124","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-012-2142-x","article-title":"Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"32","author":"Muro","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2013.844390","article-title":"Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease","volume":"24","author":"Nara","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib127","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of J01 antibody-associated antisynthetase syndrome: anti-R052 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib128","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.chest.2023.01.031_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.chest.2023.01.031_bib130","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib131","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib133","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib134","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2023.01.031_bib136","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib137","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib138","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/bjd.15499","article-title":"Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules\/papules","volume":"177","author":"Koguchi-Yoshioka","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.chest.2023.01.031_bib139","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2023.01.031_bib140","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib141","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A\u00a0case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib142","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.chest.2023.01.031_bib143","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.chest.2023.01.031_bib144","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib145","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of Tofacitinib in Refractory Dermatomyositis (STIR): an open label pilot study in refractory dermatomyositis","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.031_bib146","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2023.01.031_bib147","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1016\/j.chest.2023.01.031_bib148","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2023.01.031_bib149","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.031_bib150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2023.01.031_bib151","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.chest.2023.01.031_bib152","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.chest.2023.01.031_bib153","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03009742.2021.1995984","article-title":"Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis","volume":"52","author":"Komai","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.chest.2023.01.031_bib154","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2023.01.031_bib155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.chest.2023.01.031_bib156","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223001629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223001629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:43:29Z","timestamp":1727300609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223001629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0012369223001629"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.031","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Myositis-Associated Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}